Overview
  • ShareThis
  • Print
  • Text Size

Partnering with MannKind

MannKind is dedicated to bringing innovative therapies to patients and their caregivers, and partnering is at the core of our business strategy.

We are focused on establishing partnerships to build therapeutic programs of significant clinical and commercial value by:

• Completing the development, launch and commercialization of AFREZZA® insulin, our lead investigational candidate.

• Enhancing our pipeline of innovative product candidates targeting therapeutic areas that include diabetes, metabolic disease, cancer, pain and migraine.

• Applying our novel dry powder (Technosphere®) and device (Dreamboat® and Cricket®) technologies, coupled with our unparalleled oral inhalation R&D expertise, to support partner development efforts for their own proprietary programs and compounds.

Whether through strategic alliances, licensing arrangements and/or research collaborations, our partnering approach is based on a flexible, creative methodology designed to establish mutually beneficial relationships that are positioned to capture upside potential beyond what either partner could achieve individually.

The MannKind team would be delighted to speak with you.  To discuss partnership opportunities, please contact:

Jonathan Goldman
Vice President, Business Development
+1 (201) 983-5043
partnering@mannkindcorp.com

We welcome the opportunity to work with other organizations in order to build products of exceptional value to patients, strategic partners and investors.

Hakan Edstrom
COO, MannKind